Sold as Yutopar. Every FDA application for this active ingredient: 2 branded and 7 generic.
As of Nov 15, 2026, FDA lists 9 applications for Ritodrine Hydrochloride (sold as Yutopar), first approved Dec 12, 1980, with 0 new uses approved and 0 published complete response letters.
| Dec 12, 1980 | YutoparNDA 18555 · New formulation or manufacturer | Astrazeneca | 8 | Discontinued |
| Jul 23, 1987 | Ritodrine HydrochlorideANDA 71188 | Abraxis Pharm | 0 | Discontinued |
| Jul 23, 1987 | Ritodrine HydrochlorideANDA 71189 | Abraxis Pharm | 1 | Discontinued |
| Jan 22, 1991 | Ritodrine Hydrochloride In Dextrose 5% In Plastic ContainerANDA 71438 | Hospira | 5 | Discontinued |
| Feb 28, 1991 | Ritodrine HydrochlorideANDA 71618 | Hospira | 4 | Discontinued |
| Feb 28, 1991 | Ritodrine HydrochlorideANDA 71619 | Hospira | 5 | Discontinued |
| — | Ritodrine HclANDA 70700 | Quad Pharms | 0 | Discontinued |
| — | Ritodrine HclANDA 70701 | Quad Pharms | 0 | Discontinued |
| — | YutoparNDA 18580 | Astrazeneca | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Astrazeneca
Abraxis Pharm